Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrimethamine + sulfadiazine + folinate for congenital toxoplasmosis
jRCTs071180093Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of pyrimethamine, Sulfadiazine and folinic acid in congenital toxoplasmosis, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of psychomotor retardation. Started Feb 2020; status: recruiting.
02
Drugs
pyrimethamineSulfadiazinefolinic acid
03
Conditions
congenital toxoplasmosis
Beyond the preview
Go deeper on jRCTs071180093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180093.